PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
BMC Cancer. 2010; 10: 292.
Published online 2010 June 16. doi:  10.1186/1471-2407-10-292
PMCID: PMC2903528

Exercise and the Prevention of Oesophageal Cancer (EPOC) study protocol: a randomized controlled trial of exercise versus stretching in males with Barrett's oesophagus

Abstract

Background

Chronic gastro-oesophageal reflux disease and excessive body fat are considered principal causes of Barrett's oesophagus (a metaplastic change in the cells lining the oesophagus) and its neoplastic progression, oesophageal adenocarcinoma. Metabolic disturbances including altered levels of obesity-related cytokines, chronic inflammation and insulin resistance have also been associated with oesophageal cancer development, especially in males. Physical activity may have the potential to abrogate metabolic disturbances in males with Barrett's oesophagus and elicit beneficial reductions in body fat and gastro-oesophageal reflux symptoms. Thus, exercise may be an effective intervention in reducing oesophageal adenocarcinoma risk. However, to date this hypothesis remains untested.

The 'Exercise and the Prevention of Oesophageal Cancer Study' will determine whether 24 weeks of exercise training will lead to alterations in risk factors or biomarkers for oesophageal adenocarcinoma in males with Barrett's oesophagus. Our primary outcomes are serum concentrations of leptin, adiponectin, tumour necrosis factor-alpha, C-reactive protein and interleukin-6 as well as insulin resistance. Body composition, gastro-oesophageal reflux disease symptoms, cardiovascular fitness and muscular strength will also be assessed as secondary outcomes.

Methods/Design

A randomized controlled trial of 80 overweight or obese, inactive males with Barrett's oesophagus will be conducted in Brisbane, Australia. Participants will be randomized to an intervention arm (60 minutes of moderate-intensity aerobic and resistance training, five days per week) or a control arm (45 minutes of stretching, five days per week) for 24 weeks. Primary and secondary endpoints will be measured at baseline (week 0), midpoint (week 12) and at the end of the intervention (week 24).

Discussion

Due to the increasing incidence and very high mortality associated with oesophageal adenocarcinoma, interventions effective in preventing the progression of Barrett's oesophagus are urgently needed. We propose that exercise may be successful in reducing oesophageal adenocarcinoma risk. This primary prevention trial will also provide information on whether the protective association between physical activity and cancer is causal.

Trial Registration

ACTRN12609000401257

Background

During the past three decades, the incidence of oesophageal adenocarcinoma (AC) has risen by more than 300% in females and 500% in males; faster than any other cancer in Western Europe, America and Australia [1-5]. Moreover, the incidence of Barrett's oesophagus, the metaplastic precursor to oesophageal AC (Figure (Figure1),1), is also rising [6]. The prognosis for patients with AC is poor with a 5 year survival rate of 10-15% [7,8].

Figure 1
The Barrett's metaplasia-dysplasia-adenocarcinoma sequence.

Chronic reflux of gastric contents into the lower oesophagus is widely accepted as the primary cause of Barrett's oesophagus and oesophageal AC [9]. Recent research has demonstrated that excessive body fat is also a cause of oesophageal AC and is likely to act through promoting neoplastic progression from Barrett's oesophagus [10]. Obesity [body mass index (BMI) > 30 kg/m2] is a determinant of acid reflux [11], and has been associated with a two-fold increase in the risk of Barrett's oesophagus [12] and up to a three-fold increase in oesophageal AC risk [13,14]. Interestingly, the co-occurrence of obesity and frequent reflux symptoms increases a person's risk of Barrett's oesophagus by over 30-fold [12]. Body fat distribution also influences Barrett's oesophagus risk. Central obesity indicated by a waist circumference of > 80 cm has been shown to increase the risk of Barrett's oesophagus by over two-fold, independent of BMI and gastro-oesophageal reflux [15,16].

Adipose tissue is a dynamic endocrine organ. Adipocytes secrete numerous hormones or 'adipokines' that exhibit mitogenic activity such as leptin, adiponectin, interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α). It has been postulated that these hormones may mediate the progression of Barrett's oesophagus to cancer (Table (Table11).

Table 1
Biomarkers associated with the progression of Barrett's oesophagus to oesophageal adenocarcinoma.

Leptin

The adipokine leptin is secreted by adipocytes and gastric chief cells and is positively associated with insulin levels, inflammation and body fat. In vitro, leptin has been shown to elicit mitogenic [17-19], angiogenic [17,18,20] and anti-apoptotic [18,19] effects when administered to oesophageal AC cell lines, enhancing cellular proliferation. Leptin receptors are also present on oesophageal epithelial cells providing a pathway for signalling [21]. A recent epidemiological study reported that male patients with Barrett's oesophagus had significantly higher leptin levels than BMI-matched controls, but no such association was seen for women [22]. These findings implicate leptin as a likely candidate mediator driving the progression from Barrett's oesophagus to oesophageal AC.

Adiponectin

Adiponectin is another adipokine implicated in the biochemical pathways to oesophageal AC development. Unlike leptin, adiponectin is inversely related to obesity and has anti-inflammatory and insulin sensitising properties. Adiponectin circulates as three oligomeric isoforms: high molecular weight (HMW), medium molecular weight (MMW) and low molecular weight (LMW) adiponectin. HMW adiponectin may be the major bioactive form as decreased levels are more closely correlated with insulin resistance and metabolic dysfunction than total adiponectin [23].

In vitro, total adiponectin has been shown to act on specific receptors to increase apoptosis [24] and inhibit leptin-induced proliferation in oesophageal AC cell lines [20]. The expression of adiponectin receptors have also been shown to be reduced in Barrett's oesophagus epithelium at the mRNA level [24]. Low levels of total adiponectin have been associated with Barrett's oesophagus [25], oesophageal AC [26], and a range of other obesity-related cancers [27].

Systemic Inflammation

Individuals with Barrett's oesophagus also exhibit signs of chronic inflammation indicated by higher circulating levels of inflammatory mediators such as IL-6 [28,29] and TNF-α [30]. The protein expression of TNF-α is also notably elevated in Barrett's oesophagus tissue samples and even more so in AC tissue [31]. Additionally, TNF-α has been shown to stimulate the proliferation of oesophageal AC cell lines in vitro [31]. Further evidence of a link between inflammation and oesophageal AC comes from findings that weekly users of aspirin had a 50% reduction in oesophageal AC risk [32-34].

Insulin Resistance

Because insulin has a range of actions (mitogenic and anti-apoptotic) in addition to its effect on blood glucose concentrations, it has been postulated that hyperinsulinaemia (secondary to insulin resistance) may also drive proliferative and metaplastic changes in gastrointestinal mucosa [35]. Furthermore, elevated levels of leptin and inflammatory mediators such as TNF-α, are also characteristics of an insulin-resistant state [36].

Exercise may Modulate Oesophageal Cancer Risk

Due to the increasing incidence and very high mortality associated with oesophageal AC, interventions effective in preventing the neoplastic progression of Barrett's oesophagus are urgently needed. Although limited, there are some epidemiological data to suggest that exercise may modulate oesophageal AC risk. Data from one large cohort study suggests that ≥ 100 minutes of physical activity per week (measured by self report), compared to no physical activity is associated with a significant 32% reduction in AC risk, although this association was attenuated when further adjustment was made for BMI [37]. Higher levels of self reported occupational physical activity before the age of 65 have also been associated with a 39% decreased risk of oesophageal AC in one population-based case-control study [38].

Physical activity may act to modulate oesophageal AC risk by reversing the metabolic aberrations associated with Barrett's oesophagus and oesophageal AC. Evidence from clinical trials in overweight individuals without Barrett's oesophagus, suggests that physical activity can significantly reduce leptin concentrations with [39-41] and without [42-44] accompanying exercise induced weight-loss. Beneficial increases in adiponectin have also been observed following 4 weeks of exercise, with results remaining significant after adjusting for body weight, body fat and plasma insulin [45]. Furthermore, physical activity is considered to play an integral role in the treatment and prevention of insulin resistance [46] and has anti-inflammatory effects [47,48] which may also benefit Barrett's oesophagus patients. Finally, exercise may lead to reductions in centrally stored body fat which may subsequently reduce gastro-oesophageal reflux symptoms, contributing further to reductions in oesophageal AC risk.

Overall, preliminary data from epidemiological studies and evidence from clinical trials in overweight populations provide a strong rationale for trialing physical activity interventions in patients with Barrett's oesophagus to reduce cancer risk. To date no clinical trials have tested the hypothesis that physical activity reduces oesophageal AC risk factors in males with Barrett's oesophagus.

The aim of the "Exercise and the Prevention of Oesophageal Cancer" (EPOC) study is to determine the effect of a 24 week moderate-intensity exercise intervention versus stretching on biomarkers associated with oesophageal AC development in overweight or obese, inactive males with Barrett's oesophagus. Our primary outcomes are serum concentrations of leptin, adiponectin, TNF-α, C-reactive protein (CRP), IL-6 and insulin resistance. Secondary outcomes include body composition, gastro-oesophageal reflux symptoms, cardiovascular fitness and muscular strength.

Methods/Design

EPOC is a randomized controlled trial with participants randomized into a 24-week exercise intervention arm or a control arm (Figure (Figure2).2). All outcomes will be measured by study personnel blinded to participants' group allocation. The study is being conducted in Brisbane, Australia. The protocol has been approved by The University of Queensland Human Ethics Committee, and the Human Ethics Committees of the four participating hospitals - Royal Brisbane & Women's Hospital, Princess Alexandra Hospital, Prince Charles Hospital and The Wesley Hospital.

Figure 2
CONSORT diagram.

Participants

This study is aiming to recruit 80 males with Barrett's oesophagus. Barrett's oesophagus is defined as the abnormal appearance of the lining of the distal oesophagus (determined via endoscopy) in addition to histological evidence of intestinal metaplasia (determined via biopsy) [49]. Both newly diagnosed and prevalent cases of Barrett's oesophagus will be included. The study is limited to males only as males are twice as likely to develop oesophageal AC than females [50]. Participants must be English speaking, residing in greater Brisbane, aged 18-70 years, have a BMI between 25 kg/m2 and 34.99 kg/m2 and be performing ≤ 60 minutes per week of moderate-vigorous intensity exercise during the previous 6 weeks. Additionally, participants must not have gained or lost ≥ 5 kg of body weight during the past 6 months. Exclusion criteria include cardiac, respiratory, renal, liver, neurological or inflammatory disease. Individuals with diabetes mellitus, hypertension, hypotension, a cancer diagnosis within 5 years or orthopaedic injuries limiting exercise participation, will also be excluded.

Recruitment

Participants will be identified and recruited through gastroenterology department appointments, hospital databases and a research study database. Recruitment will take place over a period of 15 months (May 2009 - August 2010). Patients attending appointments at the gastroenterology departments of three large tertiary hospitals, one private hospital and a private gastroenterology clinic in Brisbane, Australia, are provided with an information sheet by their treating doctor and given an expression of interest form to complete. Potential participants identified by hospital personnel from hospital databases will be posted a letter and an expression of interest form. Potential participants who have expressed interest in joining the study will then be contacted by telephone by study personnel to have the study explained and be screened for eligibility. Participants will enter the study once written informed consent has been obtained.

Randomization

Participants are allocated to the intervention arm or the control arm via computerised randomization http://www.randomization.com, following completion of baseline assessment. The randomization sequence was generated by a research assistant not involved with the study. Group allocation is concealed from investigators using sealed, numbered envelopes.

Intervention Arm

Participants randomized to the intervention arm of the study undertake 60 minutes of exercise, five days per week for 24 weeks. Each session involves: 30 minutes of moderate-intensity aerobic training (60-70% of maximum heart rate) and 30 minutes of resistance training (plus a 5 minute warm-up and cool-down of light intensity). Participants perform one exercise session per week at a hospital gymnasium in small groups under the supervision of study personnel (physiotherapist/exercise physiologist). In addition, each participant is provided with a free gym membership to complete another four exercise sessions independently at a privately run health club in their local area.

Participants perform aerobic exercise on treadmills, cycling or rowing stationary ergometers and elliptical machines. During the sessions exercise intensity is measured via the unmodified (6-20) BORG scale. Participants are instructed to maintain their rate of perceived exertion between "somewhat hard" and "hard" (13-15) [51]. The resistance component consists of performing one set of 12-15 repetitions during weeks 0-8; and two sets of 8-10 repetitions during weeks 9-24. Resistance is prescribed to achieve muscular fatigue between 8-15 repetitions depending on the training phase. Exercises include: chest press, leg press, shoulder press, seated row, lunges, assisted chin up, assisted dip and core stability.

The program is consistent with the current World Cancer Research Fund and American Institute for Cancer Research recommendations for cancer prevention which advocate 30-60 minutes of moderate-intensity exercise on most if not all days of the week [10].

Control Arm

Participants allocated to the control arm attend a hospital gymnasium once a week to perform 45 minutes of stretching in small groups under the supervision of study personnel. They are also instructed to perform the stretching program independently at home, four times per week. Stretching will act as an 'attention' control condition. Participants in the control arm are instructed not to commence a new exercise program during the study. At the conclusion of the study they are offered an exercise program and a complimentary three month gym membership to a private health club in their local area.

Attendance and Adherence

Participants document the details of their independent exercise or stretching sessions daily in a physical activity diary. For participants in the intervention arm, attendance at the private health club is also electronically recorded each time they visit via their membership card. Secondary outcome measures such as cardiovascular fitness, muscular strength and body composition will also provide information regarding adherence to the protocol.

Primary Outcomes

All primary outcomes are measured at baseline (week 0), midpoint (week 12) and at the conclusion of the intervention (week 24). Biomarkers associated with oesophageal AC development will be measured as primary outcomes via blood samples. Fasting blood samples of 30 ml will be obtained by blood collectors from an accredited pathology laboratory from the antecubital vein between 08:00-10:00 am and at least 24 hours post exercise to minimize diurnal fluctuations and acute exercise effects. Blood samples will be centrifuged within 20 minutes of collection and stored at -80°C. Laboratory personnel will analyse the samples in two batches over a period of 24 months.

Serum leptin will be analysed via radioimmunoassay (RIA) (Linco Research, Missouri, USA) and serum adiponectin (total and HMW) by an enzyme-linked immunosorbent assay (ELISA) (Linco Research, Missouri, USA). The inter- and intra-assay coefficients of variation (CV) are < 8% for leptin and < 9% for adiponectin.

Fasting serum insulin will be analysed using an immunoenzymatic 'sandwich' assay via an ACCESS system (Beckman Coulter, Fullerton, USA) and plasma glucose concentrations determined with an oxygen rate method via the SYNCHRON system (Beckman Coulter, Fullerton, USA) with an inter- and intra-assay CV of < 5% for both insulin and glucose. Insulin resistance will be calculated using the reciprocal index of homeostasis model assessment (HOMA-IR) [52] and the Quantitative Insulin Sensitivity Check Index (QUICKI) [53]. Both measures calculate ratios of fasting insulin:glucose concentrations using different algorithms and have been shown to be reproducible and valid measures of insulin resistance.

Serum concentrations of CRP will be analysed using a high sensitivity Near Infrared Particle Immunoassay with the SYNCHRON system (Beckman Coulter, Fullerton, USA). Inter- and intra-assay CV is < 5%. IL-6 will be measured in serum with the Immulite 2000 analyser using an immunometric assay (Siemens, USA) with an inter- and intra-assay CV of < 7%. Serum TNF-α will be measured using a Bio-Plex suspension array system via immunoassay (Bio-Rad laboratories, Hercules, USA), with inter-assay CV of < 8% and intra-assay CV of < 6%.

Secondary Outcomes

Secondary outcomes will also be measured at week 0, 12 and 24.

Body Composition

Body fat and fat free mass will be measured in triplicate using bioimpedance spectroscopy (ImpediMed SFB7, ImpediMed Ltd., Australia). Typical coefficients of variation within a measurement session range from 0.3 to 3.0% [54]. Waist circumference will be calculated in duplicate at the midpoint between the lower costal (rib) border and the iliac crest. Hip circumference will be measured in duplicate as the maximum diameter at the greater trochanter. Waist-to-hip ratio will also be determined.

BMI will be calculated (weight [kg]/height [m]2) as it is a reasonable measure of global adiposity. Height is measured using a stadiometer to 1 mm, without shoes, arms by side and heels together. Weight is measured to the nearest 0.1 kg in light clothing, without shoes, on a calibrated scale (UC-321, A&D Co. Ltd., Japan) with an empty bladder.

Cardiovascular Fitness

Cardiovascular fitness will be estimated using peak oxygen uptake (VO2peak) during the Modified Shuttle Walk Test [55]. VO2peak will be measured using a Cortex Metamax 3 portable metabolic analyser (Cortex:biophysik, GMbH, Germany) during the test. VO2peak is the highest oxygen uptake achieved with an increasing external work rate, but unlike VO2max, a plateau in oxygen uptake may not be observed. VO2peak is a useful estimation of cardiovascular fitness as not every participant may reach VO2max before symptom limitation occurs [56].

Muscle Strength

One-repetition maximum (1 RM) tests will be performed on the bench press and leg press to measure muscle strength. 1 RM is the maximum weight a person can lift only one time with correct technique. 1 RM has shown to be a reliable and valid measure of strength in middle aged, untrained adults [57].

Gastro-oesophageal Reflux Disease

There is no gold standard test to diagnose or monitor gastro-oesophageal reflux disease [58]. Gastro-oesophageal reflux symptoms will be measured using the Gastro-esophageal Reflux Disease Impact Scale (GIS) which is short and simple to use; responsive to change over time; completed by patients and has documented internal consistency, reproducibility and construct validity [59].

Monitoring Confounding Variables

Participants will document medication use and all protocol and non-protocol exercise performed in a daily log; smoking habits will also be recorded every 4 weeks. The International Physical Activity Questionnaire (IPAQ), (long, last 7 days, self-administered format) [60,61] will also be completed by participants at week 0, 12 and 24 and will provide additional information regarding incidental, job and leisure time physical activity; and sitting time over a one week period. All participants will be instructed to maintain a consistent diet throughout the study and this will be evaluated via a Food Frequency Questionnaire completed at week 0, 12 and 24.

Sample Size Calculation

There is limited evidence on which to base the minimum detectable difference for the sample size calculation. Namely, the magnitude of change in the primary biomarker outcomes that is associated with a reduction in oesophageal AC risk is not known. A minimum difference of 10% between the means of the intervention arm and the control arm for all primary outcomes is likely to produce a clinical benefit and is achievable by the intervention. Standard deviations were based on those observed in previous clinical trials investigating the effect of exercise on overweight or obese, inactive, healthy males. Thus, a sample size of 40 participants per group (80 in total) is needed to detect a minimal difference of 10% in primary outcomes between groups, with 80% power, a type I error of 5% and allowing for 10% attrition (two-tailed).

Statistical Analysis

Generalised linear models, estimating variance appropriately for repeated measures, will be used to determine whether there are differences between the exercise intervention group and the control group in primary and secondary outcomes. Models will be adjusted for baseline outcome values, to account for regression to the mean, as well as the main effects of group, time and their interaction. Mediation and moderation of intervention effects will be examined with change in body weight, body fat, minutes exercised per week and VO2peak considered a priori to be of potential interest. Analyses will be performed using intention-to-treat principles and on a per-protocol basis. Statistical significance will be set at p < 0.05 (two-tailed).

Discussion

The EPOC study aims to determine whether exercise can modulate the biochemical pathways to oesophageal cancer development in males with the pre-malignant condition Barrett's oesophagus. Exercise may prove to be an effective intervention in reducing the risk of oesophageal AC development which would have important health implications for males with Barrett's oesophagus.

Moreover, findings from the EPOC study will help to further define the role of exercise in the primary prevention of cancer by adding to the limited number of clinical trials of exercise interventions and cancer-related biomarkers [62-71]. As participants targeted by the EPOC study may be at an even higher cancer risk than those previously studied, greater exercise intervention effects may be observed. Lastly, the biological mechanisms underlying the inverse association between physical activity and carcinogenesis can be further explored.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

DCW developed the study concept. BMW, DCW and JDP developed the study protocol. BMW drafted the manuscript. All authors contributed to the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/10/292/prepub

Acknowledgements

The project has been funded by grants from The Wesley Research Institute and Queensland Health (Cancer Care Allied Health Research Scheme). We would like to thank Goodlife Health Clubs Brisbane for donating gym memberships to our participants. BMW is supported by an Australian Postgraduate Award. DCW is a Principal Research Fellow and MMR is a Training Research Fellow of the National Health and Medical Research Council of Australia.

References

  • Blot WJ, Devesa SS, Kneller RW. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991;265:1287–1296. doi: 10.1001/jama.265.10.1287. [PubMed] [Cross Ref]
  • Lord RV, Law MG, Ward RL, Giles GG, Thomas RJ, Thursfield V. Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol. 1998;13(4):356–362. doi: 10.1111/j.1440-1746.1998.tb00646.x. [PubMed] [Cross Ref]
  • Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part I: Overall and upper gastrointestinal diseases. Gastroenterology. 2009;136:376–386. doi: 10.1053/j.gastro.2008.12.015. [PubMed] [Cross Ref]
  • Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer. 2002;99:860–868. doi: 10.1002/ijc.10427. [PubMed] [Cross Ref]
  • Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–146. doi: 10.1093/jnci/dji024. [PubMed] [Cross Ref]
  • Kendall BJ, Whiteman DC. Temporal changes in the endoscopic frequency of new cases of Barrett's oesophagus in an Australian health region. Am J Gastroenterol. 2006;101:1178–1182. doi: 10.1111/j.1572-0241.2006.00548.x. [PubMed] [Cross Ref]
  • Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin. 2005;55:74–108. doi: 10.3322/canjclin.55.2.74. [PubMed] [Cross Ref]
  • Polednak AP. Trends in survival for both histological types of esophageal cancer in US Surveillance, Epidemiology and End Results areas. Int J Cancer. 2003;105:98–100. doi: 10.1002/ijc.11029. [PubMed] [Cross Ref]
  • Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825–831. doi: 10.1056/NEJM199903183401101. [PubMed] [Cross Ref]
  • World Cancer Research Fund/American Institute for Cancer Research. The second expert report: food, nutrition, physical activity and the prevention of cancer: a global perspective. Washington DC: American Institute for Cancer Research; 2007. [PubMed]
  • Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130(3):639–649. doi: 10.1053/j.gastro.2005.12.016. [PubMed] [Cross Ref]
  • Smith KJ, O'Brien SM, Smithers M, Gotley DC, Webb PM, Green A, Whiteman DC. Interactions among smoking, obesity and symptoms of acid reflux in Barrett's oesophagus. Cancer Epidemiol Biomarkers Prev. 2005;14:2481–2486. doi: 10.1158/1055-9965.EPI-05-0370. [PMC free article] [PubMed] [Cross Ref]
  • Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143:199–211. [PubMed]
  • Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, Webb PM, Green AC. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut. 2008;57:173–180. doi: 10.1136/gut.2007.131375. [PubMed] [Cross Ref]
  • Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett's esophagus. Gastroenterology. 2007;133:403–411. doi: 10.1053/j.gastro.2007.05.026. [PubMed] [Cross Ref]
  • Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Quesenberry C, Rumore GJ, Buffler PA. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology. 2007;133:34–41. doi: 10.1053/j.gastro.2007.04.046. [PubMed] [Cross Ref]
  • Somasundar P, Riggs D, Jacksona B, Vona-Davis L, McFadden DW. Leptin stimulates esophageal adenocarcinoma growth by nonapoptotic mechanisms. Am J Surg. 2003;186:575–578. doi: 10.1016/j.amjsurg.2003.07.017. [PubMed] [Cross Ref]
  • Beales IL, Ogunwobi OO. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol. 2007;274(1-2):60–68. doi: 10.1016/j.mce.2007.05.017. [PubMed] [Cross Ref]
  • Ogunwobi O, Mutungi G, Beales IL. Leptin stimulates proliferation and inhibits apoptosis in Barrett's oesophageal adenocarcinoma cells by cyclooxygenase-2-dependent, prostaglandin-E2-mediated transactivation of the epidermal growth factor receptor and c-Jun NH2-terminal kinase activation. Endocrinology. 2006;147:4505–4516. doi: 10.1210/en.2006-0224. [PubMed] [Cross Ref]
  • Ogunwobi OO, Beales IL. Globular adiponectin, acting via adiponectin receptor-1, inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol. 2008;285(1-2):43–50. doi: 10.1016/j.mce.2008.01.023. [PubMed] [Cross Ref]
  • Francois F, Roper J, Goodman AJ, Pei Z, Ghumman M, Mourad M, de Perez AZ, Perez-Perez GI, Tseng CH, Blaser MJ. The association of gastric leptin with oesophageal inflammation and metaplasia. Gut. 2008;57(1):16–24. doi: 10.1136/gut.2007.131672. [PubMed] [Cross Ref]
  • Kendall BJ, Macdonald GA, Hayward NK, Prins JB, Brown I, Walker N, Pandeya N, Green AC, Webb PM, Whiteman DC. Leptin and the risk of Barrett's oesophagus. Gut. 2008;57:448–454. doi: 10.1136/gut.2007.131243. [PubMed] [Cross Ref]
  • Wang Y, Lam KSL, Yau M-h, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J. 2008;409(3):623–633. doi: 10.1042/BJ20071492. [PubMed] [Cross Ref]
  • Konturek PC, Burnat G, Rau T, Hahn EG, Konturek S. Effect of adiponectin and ghrelin on apoptosis of Barrett adenocarcinoma cell line. Dig Dis Sci. 2008;53(3):597–605. doi: 10.1007/s10620-007-9922-1. [PubMed] [Cross Ref]
  • Rubenstein JH, Dahlkemper A, Kao JY, Zhang M, Morgenstern H, McMahon L, Inadomi JM. A pilot study of the association of low plasma adiponectin and Barrett's esophagus. Am J Gastroenterol. 2008;103(6):1358–1364. doi: 10.1111/j.1572-0241.2008.01823.x. [PubMed] [Cross Ref]
  • Yildirim A, Bilici M, Cayir K, Yanmaz V, Yildirim S, Tekin SB. Serum adiponectin levels in patients with esophageal cancer. Jpn J Clin Oncol. 2009;39(2):92–96. doi: 10.1093/jjco/hyn143. [PubMed] [Cross Ref]
  • Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. Br J Cancer. 2006;94:1221–1225. doi: 10.1038/sj.bjc.6603051. [PMC free article] [PubMed] [Cross Ref]
  • Moons LMG, Kusters JG, Bultman E, Kuipers EJ, Van Dekken H, Tra WMW, Kleinjan A, Kwekkeboom J, van Vliet AHM, Siersema PD. Barrett's oesophagus is characterised by a predominantly humoral inflammatory response. J Pathol. 2005;207:269–276. doi: 10.1002/path.1847. [PubMed] [Cross Ref]
  • Dvorakova K, Payne C, Ramsey L. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res. 2004;10:2020–2028. doi: 10.1158/1078-0432.CCR-0437-03. [PubMed] [Cross Ref]
  • Eksteen JA, Scott PA, Perry I, Jankowski JA. Inflammation promotes Barrett's metaplasia and cancer: a unique role for TNF-alpha. Eur J Cancer Prev. 2001;10:163–166. doi: 10.1097/00008469-200104000-00008. [PubMed] [Cross Ref]
  • Tselepis C, Perry I, Dawson C, Hardy R, Darnton SJ, McConkey C, Stuart RC, Wright N, Harrison R, Jankowski JA. Tumour necrosis factor-a in Barrett's oesophagus: a potential novel mechanism of action. Oncogene. 2002;21:6071–6081. doi: 10.1038/sj.onc.1205731. [PubMed] [Cross Ref]
  • Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green A, Whiteman DC. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev. 2008;17(5):1–10. doi: 10.1158/1055-9965.EPI-07-2852. [PubMed] [Cross Ref]
  • Vaughan TL, Dong LM, Blount PL, Ayub K, Odze R, Sanchez CA, Rabinovitch PS, Reid BJ. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncology. 2005;6:945–952. doi: 10.1016/S1470-2045(05)70431-9. [PubMed] [Cross Ref]
  • Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastrenterol. 2003;124:47–56. doi: 10.1053/gast.2003.50008. [PubMed] [Cross Ref]
  • Komninou D, Ayonote A, Richie JP Jr, Rigas B. Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med (Maywood) 2003;228(4):396–405. [PubMed]
  • Boyd DB. Insulin and cancer. Integr Cancer Ther. 2003;2(4):315–329. doi: 10.1177/1534735403259152. [PubMed] [Cross Ref]
  • Leitzmann MF, Koebnick C, Freedman ND, Park Y, Ballard-Barbash R, Hollenbeck A, Schatzkin A, Abnet CC. Physical activity and esophageal and gastric carcinoma in a large prospective study. Am J Prev Med. 2009;36(2):112–119. doi: 10.1016/j.amepre.2008.09.033. [PMC free article] [PubMed] [Cross Ref]
  • Vigen C, Bernstein L, Wu AH. Occupational physical activity and risk of adenocarcinomas of the esophagus and stomach. Int J Cancer. 2006;118(4):1004–1009. doi: 10.1002/ijc.21419. [PubMed] [Cross Ref]
  • Perusse L, Collier G, Gagnon J, Leon AS, Rao DC, Skinner JS, Wilmore JH, Nadeau A, Zimmet PZ, Bouchard C. Acute and chronic effects of exercise on leptin levels in humans. J Appl Physiol. 1997;83(1):5–10. [PubMed]
  • Fatouros IG, Tournis S, Leontsini D, Jamurtas AZ, Sxina M, Thomakos P, Manousaki M, Douroudos I, Taxildaris K, Mitrakou A. Leptin and adiponectin responses in overweight inactive elderly following resistance training and detraining are intensity related. J Clin Endocrinol Metab. 2005;90(11):5970–5977. doi: 10.1210/jc.2005-0261. [PubMed] [Cross Ref]
  • Thong FSL, Hudson R, Ross R, Janssen I, Graham TE. Plasma leptin in moderately obese men: independent effects of weight loss and aerobic exercise. Am J Physiol-Endocrinol Metab. 2000;279(2):E307–E313. [PubMed]
  • Reseland JE, Anderssen SA, Solvoll K, Hjermann I, Urdal P, Holme I, Drevon CA. Effect of long-term changes in diet and exercise on plasma leptin concentrations. Am J Clin Nutrition. 2001;73(2):240–245. [PubMed]
  • Pasman WJ, Westerterp-Plantenga MS, Saris WH. The effect of exercise training on leptin levels in obese males. Am J Physiol. 1998;274(2):E280–286. [PubMed]
  • Ishii T, Yamakita T, Yamagami K, Yamamoto T, Miyamoto m, Koichi Kawasaki, Masayuki Hosoi, Katsunobu Yoshioka, Toshihiko Sato, Shiro Tanaka. Effect of exercise training on serum leptin levels in type 2 diabetic patients. Metabolism. 2001;50(10):1136–1140. doi: 10.1053/meta.2001.26745. [PubMed] [Cross Ref]
  • Bluher M, Bullen JW, Lee JH, Kralisch S, Fasshauer M, Kloting N, Niebauer J, Schon MR, Williams CJ, Mantzoros CS. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: Associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab. 2006;91(6):2310–2316. doi: 10.1210/jc.2005-2556. [PubMed] [Cross Ref]
  • Borghouts LB, Keizer HA. Exercise and insulin sensitivity: A review. Int J Sports Med. 2000;21(1):1–12. doi: 10.1055/s-2000-8847. [PubMed] [Cross Ref]
  • Lakka TA, Lakka H-M, Rankinen T, Leon AS, Rao DC, Skinner JS, Wilmore JH, Bouchard C. Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study. Eur Heart J. 2005;26(19):2018–2025. doi: 10.1093/eurheartj/ehi394. [PubMed] [Cross Ref]
  • Milani RV, Lavie CJ, Mehra MR. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. J Am Coll Cardiol. 2004;43:1056–1061. doi: 10.1016/j.jacc.2003.10.041. [PubMed] [Cross Ref]
  • Sharma P, McQuaid K, Dent J, Fennerty B, Sampliner RE, Spechler SJ, Cameron AJ, Corley DA, Falk GW, Goldblum J. A critical review of the diagnosis and management of Barrett's esophagus:The AGA Chicago Workshop. Gastrenterology. 2004;127:310–330. doi: 10.1053/j.gastro.2004.04.010. [PubMed] [Cross Ref]
  • Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high grade dysplasia in Barrett's esophagus: A systematic review and meta-analysis. Am J Epidemiol. 2008;168:237–249. doi: 10.1093/aje/kwn121. [PubMed] [Cross Ref]
  • Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med. 1970;2:92–99. [PubMed]
  • Mathews DR, Hosker JR, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–121. doi: 10.1007/BF00280883. [PubMed] [Cross Ref]
  • Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–2410. doi: 10.1210/jc.85.7.2402. [PubMed] [Cross Ref]
  • Cornish B. The Evaluation of multiple frequency bioelectrical impedance analysis for the assessment of body water volumes in healthy humans. Eur J Clin Nutr. 1996;50:159–164. [PubMed]
  • Singh S, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax. 1992;47:1019–1024. doi: 10.1136/thx.47.12.1019. [PMC free article] [PubMed] [Cross Ref]
  • Fletcher G. Exercise standards for testing and training: a statement for healthcare professionals from the American heart Association. Circulation. 2001;104:1694–1740. doi: 10.1161/hc3901.095960. [PubMed] [Cross Ref]
  • Levinger I, Goodman C, Hare DL, Jerums G, Toia D, Selig S. The reliability of the 1RM strength test for untrained, middle-aged individuals. J Sci Med in Sport. 2009;12:310–316. doi: 10.1016/j.jsams.2007.10.007. [PubMed] [Cross Ref]
  • Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086–2100. doi: 10.1016/S0140-6736(06)68932-0. [PubMed] [Cross Ref]
  • Jones R, Coyne K, Wiklund I. The Gastro-oesophageal Reflux Disease Impact Scale: a patient management tool for primary care. Aliment Pharmacol Ther. 2007;25(12):1451–1459. [PubMed]
  • Hallal PC, Victora CG. Reliability and validity of the International Physical Activity Questionnaire (IPAQ) Med Sci Sports Exerc. 2004. p. 556. [PubMed] [Cross Ref]
  • Booth ML. Assessment of physical activity: an international perspective. Res Q Exercise Sport. 2000;71(2):s114–120. [PubMed]
  • Abrahamson PE, King IB, Ulrich CM, Rudolph RE, Irwin ML, Yasui Y, Surawicz C, Lampe JW, Lampe PD, Morgan A. No effect of exercise on colon mucosal prostaglandin concentrations: A 12-month randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2351–2356. doi: 10.1158/1055-9965.EPI-07-0120. [PubMed] [Cross Ref]
  • Campbell KL, McTiernan A, Li SS, Sorensen B, Yasui Y, Lampe JW, King IB, Ulrich C, Rudolph R, Irwin M. Effect of a 12-month exercise intervention on the apoptotic regulating proteins Bax and Bcl-2 in colon crypts: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1767–1774. doi: 10.1158/1055-9965.EPI-07-0291. [PubMed] [Cross Ref]
  • McTiernan A, Yasui Y, Sorensen B, Irwin ML, Morgan A, Rudolph RE, Surawicz C, Lampe JW, Ayub K, Potter JD. Effect of a 12-month exercise intervention on patterns of cellular proliferation in colonic crypts: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev. 2006;15(9):1588–1597. doi: 10.1158/1055-9965.EPI-06-0223. [PubMed] [Cross Ref]
  • McTiernan A, Tworoger S, Ulrich C, Yasui Y, Irwin M, Rajan K, Sorensen B, Rudolph R, Bowen D, Stanczyk F. Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial. Cancer Res. 2004;64:2923–2928. doi: 10.1158/0008-5472.CAN-03-3393. [PubMed] [Cross Ref]
  • Monninkhof EM, Velthuis MJ, Peeters PHM, Twisk JWR, Schuit AJ. Effect of exercise on postmenopausal sex hormone levels and role of body fat: a randomized controlled trial. J Clin Oncol. 2009;27(27):4492–4499. doi: 10.1200/JCO.2008.19.7459. [PubMed] [Cross Ref]
  • McTiernan A, Tworoger S, Rajan K, Yasui Y, Sorensen B, Ulrich C, Chubak J, Stanczyk F, Bowen D, Irwin M. Effect of exercise on serum androgens in postmenopausal women: a 12-month randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2004;13(7):1099–1105. [PubMed]
  • Frank L, Sorensen B, Yasui Y, Tworoger S, Schwartz R, Ulrich C, Irwin M, Rudolph R, Rajan K, Stanczyk F. Effects of exercise on metabolic risk variables in overweight postmenopausal women: a randomized clinical trial. Obes Res. 2005;13(3):615–625. doi: 10.1038/oby.2005.66. [PubMed] [Cross Ref]
  • Atkinson C, Lampe JW, Tworoger S, Ulrich C, Bowen D, Irwin M, Schwartz R, Rajan K, Yasui Y, Potter J. Effects of a moderate intensity exercise intervention on estrogen metabolism in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004;13(5):868–874. [PubMed]
  • McTiernan A, Sorensen B, Yasui Y, Tworoger S, Ulrich C, Irwin M, Rudolph R, Stanczyk F, Schwartz R, Potter J. No effect of exercise on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in postmenopausal women: a 12-month randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2005;14(4):1020–1021. doi: 10.1158/1055-9965.EPI-04-0834. [PubMed] [Cross Ref]
  • Friedenreich CM, Woolcott CG, McTiernan A, Ballard-Barbash R, Brant RF, Stanczyk FZ, Terry T, Boyd NF, Yaffe MJ, Irwin ML. Alberta physical activity and breast cancer prevention trial: sex hormone changes in a year-long exercise intervention among postmenopausal women. J Clin Oncol. 2010;28(9):1458–1466. doi: 10.1200/JCO.2009.24.9557. [PMC free article] [PubMed] [Cross Ref]

Articles from BMC Cancer are provided here courtesy of BioMed Central